In a crossover design, control of blood pressure by extended release felodipine was compared with control by prolonged action nifedipine in 21 children with renal hypertension. Compliance with once daily felodipine was higher than with nifedipine, at 95-6 (SEM 2.7)% v 78 9 (60)% (p=0-02).
A new dihydropyridine calcium antagonist, felodipine, was introduced in 1991 and has also been found to be effective in adults. 5 6 This drug is available as an extended release (ER) formulation which has the advantage of once daily administration and potentially improved compliance.
The issue of compliance with chronic medications in children is a serious problem, and attempts to decrease the frequency of drug dosage are a potential way of improving compliance.7 The objective of our study was to evaluate the effectiveness of felodipine-ER (Plendil, Astra Pharma) by comparing it with nifedipine-PA (Adalat, Miles) in the treatment of children with hypertension predominantly due to renal disease, in a randomised crossover design. We also assessed improvement in patients' compliance during use of once daily felodipine-ER. To the best of our knowledge this is the first paediatric study with this agent.
Methods

PATIENTS
Twenty one hypertensive children between the ages of 6 and 18 years who had been receiving nifedipine-PA treatment were asked to participate in the study. Most of these patients (18/21) had undergone renal transplantation. Before initiating this protocol, home and clinic blood pressure had been followed closely and exceeded the 95th centile for normal subjects of matched age and gender for at least four out of seven days of the week with two measurements per day. Patients were excluded if their control or treatment of hypertension had been unstable during the preceding month or if they were unable to swallow the 9 mm diameter felodipine tablet.
The study protocol was approved by our hospital's research ethics committee.
PROCEDURES
Eligible patients were randomised by a random number table to receive treatment with felodipine-ER or nifedipine-PA for one month and then crossed over to the other agent. Patients and parents were not blinded to the study drugs because of the different appearance and dosage schedules, but the physicians in the clinic were unaware of the assigned drugs for the duration of the study. The starting dose of felodipine was set at one quarter of the nifedipine daily dose5 6 up to a maximum of 20 mg per day. Dose adjustments were Felodipine versus nifedipine in hypertension We recorded concomitant antihypertensive drugs such as 13 blockers and diuretics as well as other ongoing medications such as prednisone, cyclosporin, and azathioprine. We also followed changes in body weight and plasma creatinine through the individual courses of therapy. 
Results
Both drugs were well tolerated by all participants and there were no dropouts. Children received a mean nifedipine dose of 58-9 (5-1) mg/d and felodipine at 13 4 (1 1) mg/d. There were no differences in the doses of concomitant drugs (other antihypertensives, prednisone, cyclosporin) given during the two arms of the study, and serum creatinine did not differ between the two phases. During the day, diastolic blood pressure with felodipine was significantly lower than with nifedipine (table 1) . A similar trend with systolic blood pressure was not statistically significant. During the night the trends reversed, with nifedipine tending to be associated with lower blood pressure; however, the trend did not reach statistical significance. Similar effects were documented with the percentage of time the blood pressure was above the 95% percentile for age (table 1) .
Compliance (that is, percentage of drug taken v prescribed) was significantly higher with felodipine (table 2) . Compliance with the evening dose of nifedipine tended to be better than with the morning dose, at 84-7 (7.7)% v 73-5 (6-6)%, p=0-17.
Discussion
This study documents good one month effectiveness of the extended release calcium channel blocker felodipine in children with renal hypertension. The better blood pressure control with felodipine during the day can be explained by the substantially better measured compliance with this once daily drug as compared with the twice daily nifedipine. There is evidence to show that compliance is inversely related to the number of pills taken by patients.7 The trend towards better compliance with nifedipine at night than during the day may be explained by more intensive parental supervision in the evening. We have recently documented a similar trend with 6-mercaptopurine in children with leukaemia (Lau R, Greenberg M, Koren G. Personal communication).
During the night it is possible that the second dose of nifedipine allowed better control of blood pressure, although the differences were not clinically significant. In our study the felodipine dose was set at one quarter of the nifedipine dose; however, based on our cumulative experience it appears that some children need higher doses to assure optimal control of blood pressure. Recent clinical experience in both children and adults has confirmed these observations. In summary, these data suggest that once daily felodipine can be successfully given to children with hypertension. It is likely that over longer study periods the differences in compliance in favour of this drug would have been even larger.
